Retatrutide is the molecule that is going to make Wegovy look modest. It is the next generation of GLP-1 development, still in trials, and the data coming out of phase 2 is the kind of data that reshapes a field.
What it actually is
Retatrutide is an investigational peptide from Eli Lilly, the same lab that brought tirzepatide (Mounjaro and Zepbound) to market. It goes one step further than tirzepatide. Where Wegovy hits one receptor and Zepbound hits two, retatrutide hits three: GLP-1, GIP, and glucagon. Each receptor is a separate lever the body uses to regulate appetite, energy expenditure, and glucose handling. The strategy is to pull all three at once.
How it works
GLP-1 you already know about: appetite suppression via brain receptors, slowed gastric emptying, glucose-dependent insulin secretion.
GIP, glucose-dependent insulinotropic polypeptide, is the other major incretin hormone. Its role in obesity has been controversial for decades. Some early studies suggested GIP agonism might worsen obesity. The tirzepatide trials settled the argument: combined GIP and GLP-1 agonism produces more weight loss than GLP-1 alone, probably because GIP works on both adipocytes and central appetite circuits in ways that complement GLP-1.
Glucagon agonism is the genuinely new thing. We have spent decades of GLP-1 research trying to suppress glucagon, because in diabetes it raises blood sugar. But it turns out glucagon also increases energy expenditure by activating brown adipose tissue, which burns calories rather than stores them. It also reduces liver fat by promoting fatty acid oxidation in hepatocytes. The trick was finding a balance between the appetite-suppressing GLP-1 effect (which lowers food in) and the metabolism-raising glucagon effect (which raises calories out) without crashing blood sugar in the process. Retatrutide is the first molecule to thread that needle in a clinical trial.
What the trials show
The phase 2 trial published in NEJM in 2023 enrolled 338 adults with obesity and randomized them across multiple doses of retatrutide and a placebo arm, treated for 48 weeks. At the highest dose (12mg weekly), the mean weight loss was 24.2 percent. The placebo arm lost 2.1 percent.
For context: that 24.2 percent number is approximately what you see in the first year after gastric bypass surgery. No drug had ever produced that level of weight loss in a phase 2 trial in this class. And the curve at week 48 had not plateaued. The trial ended before the participants stopped losing.
A separate analysis looked at liver fat content in participants with elevated baseline values. Liver fat dropped by an average of 82 percent in the high-dose arm at week 24. That has implications for non-alcoholic fatty liver disease, which has no good drug treatments and is the leading cause of liver transplant in the United States.
The phase 3 program, called TRIUMPH, is currently running across multiple indications: obesity alone, obesity with type 2 diabetes, NAFLD, obstructive sleep apnea. Approval is anticipated in 2027, assuming the trials confirm the phase 2 effect at scale.
What you actually feel
Reports from trial participants and from grey-market users echo the GLP-1 experience but more intense. Nausea is more common in the early weeks. Energy expenditure increases, which some users describe as feeling warmer or sleeping less deeply. The appetite suppression is reportedly stronger than with semaglutide or tirzepatide, particularly at the higher doses.
Side effects
The class effects show up: GI symptoms, particularly in the first 12 weeks. The new wrinkle with retatrutide is heart rate. The glucagon arm appears to raise resting heart rate by 3 to 7 beats per minute on average. Whether this matters clinically over years of treatment is one of the things phase 3 is designed to answer.
Transient liver enzyme elevations have been reported at high doses, which is a slightly weird finding given that liver fat improves so dramatically. The interpretation is still open. The most likely story is that the rapid liver fat mobilization itself stresses the hepatocyte machinery temporarily.
Status
Not approved. Not legal to obtain through normal pharmaceutical channels in most jurisdictions. Some compounding pharmacies in the US operate in a regulatory grey zone where they produce semaglutide and tirzepatide compounds. A few have started producing retatrutide-adjacent formulations as well. Quality and identity of these products varies.
There is no good reason to take retatrutide right now if you have access to semaglutide or tirzepatide, and several reasons not to. The phase 3 readout will give us better safety data on a larger population. Approval will give us a guaranteed-quality product. Both are worth waiting for unless you have a clinical need that the existing GLP-1 drugs are not meeting.
The honest closing
Retatrutide is the kind of molecule that will likely reshape how we treat obesity, diabetes, and fatty liver disease together as a single metabolic problem rather than three separate ones. Whether you should personally use it before phase 3 reads out and approval lands is a different question, and the answer for most people is no.
See it on you
If you are curious what the kind of weight loss retatrutide produces could look like on your specific body, PepScan generates the projection from one photo. It is worth seeing what the upper end of the GLP-1 era could mean for your frame before you start watching the approval timeline.